CINXE.COM

<!DOCTYPE html> <html lang="en" dir="ltr"> <head>  <script async src="https://www.googletagmanager.com/gtag/js?id=G-P63WKM1TM1"></script> <script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-P63WKM1TM1'); </script>  <script type="text/javascript" > (function(m,e,t,r,i,k,a){m[i]=m[i]||function(){(m[i].a=m[i].a||[]).push(arguments)}; m[i].l=1*new Date(); for (var j = 0; j < document.scripts.length; j++) {if (document.scripts[j].src === r) { return; }} k=e.createElement(t),a=e.getElementsByTagName(t)[0],k.async=1,k.src=r,a.parentNode.insertBefore(k,a)}) (window, document, "script", "https://mc.yandex.ru/metrika/tag.js", "ym"); ym(55165297, "init", { clickmap:false, trackLinks:true, accurateTrackBounce:true, webvisor:false }); </script> <noscript><div><img src="https://mc.yandex.ru/watch/55165297" style="position:absolute; left:-9999px;" alt="" /></div></noscript>    <title>Search results for: malignant mixed mullerian tumor</title> <meta name="description" content="Search results for: malignant mixed mullerian tumor"> <meta name="keywords" content="malignant mixed mullerian tumor"> <meta name="viewport" content="width=device-width, initial-scale=1, minimum-scale=1, maximum-scale=1, user-scalable=no"> <meta charset="utf-8"> <link href="https://cdn.waset.org/favicon.ico" type="image/x-icon" rel="shortcut icon"> <link href="https://cdn.waset.org/static/plugins/bootstrap-4.2.1/css/bootstrap.min.css" rel="stylesheet"> <link href="https://cdn.waset.org/static/plugins/fontawesome/css/all.min.css" rel="stylesheet"> <link href="https://cdn.waset.org/static/css/site.css?v=150220211555" rel="stylesheet"> </head> <body> <header> <div class="container"> <nav class="navbar navbar-expand-lg navbar-light"> <a class="navbar-brand" href="https://waset.org"> <img src="https://cdn.waset.org/static/images/wasetc.png" alt="Open Science Research Excellence" title="Open Science Research Excellence" /> </a> <button class="d-block d-lg-none navbar-toggler ml-auto" type="button" data-toggle="collapse" data-target="#navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"> <span class="navbar-toggler-icon"></span> </button> <div class="w-100"> <div class="d-none d-lg-flex flex-row-reverse"> <form method="get" action="https://waset.org/search" class="form-inline my-2 my-lg-0"> <input class="form-control mr-sm-2" type="search" placeholder="Search Conferences" value="malignant mixed mullerian tumor" name="q" aria-label="Search"> <button class="btn btn-light my-2 my-sm-0" type="submit"><i class="fas fa-search"></i></button> </form> </div> <div class="collapse navbar-collapse mt-1" id="navbarMenu"> <ul class="navbar-nav ml-auto align-items-center" id="mainNavMenu"> <li class="nav-item"> <a class="nav-link" href="https://waset.org/conferences" title="Conferences in 2024/2025/2026">Conferences</a> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/disciplines" title="Disciplines">Disciplines</a> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/committees" rel="nofollow">Committees</a> </li> <li class="nav-item dropdown"> <a class="nav-link dropdown-toggle" href="#" id="navbarDropdownPublications" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false"> Publications </a> <div class="dropdown-menu" aria-labelledby="navbarDropdownPublications"> <a class="dropdown-item" href="https://publications.waset.org/abstracts">Abstracts</a> <a class="dropdown-item" href="https://publications.waset.org">Periodicals</a> <a class="dropdown-item" href="https://publications.waset.org/archive">Archive</a> </div> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/page/support" title="Support">Support</a> </li> </ul> </div> </div> </nav> </div> </header> <main> <div class="container mt-4"> <div class="row"> <div class="col-md-9 mx-auto"> <form method="get" action="https://publications.waset.org/abstracts/search"> <div id="custom-search-input"> <div class="input-group"> <i class="fas fa-search"></i> <input type="text" class="search-query" name="q" placeholder="Author, Title, Abstract, Keywords" value="malignant mixed mullerian tumor"> <input type="submit" class="btn_search" value="Search"> </div> </div> </form> </div> </div> <div class="row mt-3"> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Commenced</strong> in January 2007</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Frequency:</strong> Monthly</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Edition:</strong> International</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Paper Count:</strong> 3725</div> </div> </div> </div> <h1 class="mt-3 mb-3 text-center" style="font-size:1.6rem;">Search results for: malignant mixed mullerian tumor</h1> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">3725</span> Blood Thicker Than Water: A Case Report on Familial Ovarian Cancer</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Joanna%20Marie%20A.%20Paulino-Morente">Joanna Marie A. Paulino-Morente</a>, <a href="https://publications.waset.org/abstracts/search?q=Vaneza%20Valentina%20L.%20Penolio"> Vaneza Valentina L. Penolio</a>, <a href="https://publications.waset.org/abstracts/search?q=Grace%20Sabado"> Grace Sabado</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Ovarian cancer is extremely hard to diagnose in its early stages, and those afflicted at the time of diagnosis are typically asymptomatic and in the late stages of the disease, with metastasis to other organs. Ovarian cancers often occur sporadically, with only 5% associated with hereditary mutations. Mutations in the BRCA1 and BRCA2 tumor suppressor genes have been found to be responsible for the majority of hereditary ovarian cancers. One type of ovarian tumor is Malignant Mixed Mullerian Tumor (MMMT), which is a very rare and aggressive type, accounting for only 1% of all ovarian cancers. Reported is a case of a 43-year-old G3P3 (3003), who came into our institution due to a 2-month history of difficulty of breathing. Family history reveals that her eldest and younger sisters both died of ovarian malignancy, with her younger sister having a histopathology report of endometrioid ovarian carcinoma, left ovary stage IIIb. She still has 2 asymptomatic sisters. Physical examination pointed to pleural effusion of right lung, and presence of bilateral ovarian new growth, which had a Sassone score of 13. Admitting Diagnosis was G3P3 (3003), Ovarian New Growth, bilateral, Malignant; Pleural effusion secondary to malignancy. BRCA was requested to establish a hereditary mutation; however, the patient had no funds. Once the patient was stabilized, TAHBSO with surgical staging was performed. Intraoperatively, the pelvic cavity was occupied by firm, irregularly shaped ovaries, with a colorectal metastasis. Microscopic sections from both ovaries and the colorectal metastasis had pleomorphic tumor cells lined by cuboidal to columnar epithelium exhibiting glandular complexity, displaying nuclear atypia and increased nuclear-cytoplasmic ratio, which are infiltrating the stroma, consistent with the features of Malignant Mixed Mullerian Tumor, since MMMT is composed histologically of malignant epithelial and sarcomatous elements. In conclusion, discussed is the clinic-pathological feature of a patient with primary ovarian Malignant Mixed Mullerian Tumor, a rare malignancy comprising only 1% of all ovarian neoplasms. Also, by understanding the hereditary ovarian cancer syndromes and its relation to this patient, it cannot be overemphasized that a comprehensive family history is really fundamental for early diagnosis. The familial association of the disease, given that the patient has two sisters who were diagnosed with an advanced stage of ovarian cancer and succumbed to the disease at a much earlier age than what is reported in the general population, points to a possible hereditary syndrome which occurs in only 5% of ovarian neoplasms. In a low-resource setting, being in a third world country, the following will be recommended for monitoring and/or screening women who are at high risk for developing ovarian cancer, such as the remaining sisters of the patient: 1) Physical examination focusing on the breast, abdomen, and rectal area every 6 months. 2) Transvaginal sonography every 6 months. 3) Mammography annually. 4) CA125 for postmenopausal women. 5) Genetic testing for BRCA1 and BRCA2 will be reserved for those who are financially capable. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=BRCA" title="BRCA">BRCA</a>, <a href="https://publications.waset.org/abstracts/search?q=hereditary%20breast-ovarian%20cancer%20syndrome" title=" hereditary breast-ovarian cancer syndrome"> hereditary breast-ovarian cancer syndrome</a>, <a href="https://publications.waset.org/abstracts/search?q=malignant%20mixed%20mullerian%20tumor" title=" malignant mixed mullerian tumor"> malignant mixed mullerian tumor</a>, <a href="https://publications.waset.org/abstracts/search?q=ovarian%20cancer" title=" ovarian cancer"> ovarian cancer</a> </p> <a href="https://publications.waset.org/abstracts/33478/blood-thicker-than-water-a-case-report-on-familial-ovarian-cancer" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/33478.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">289</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">3724</span> An Insight into Early Stage Detection of Malignant Tumor by Microwave Imaging </h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Muhammad%20Hassan%20Khalil">Muhammad Hassan Khalil</a>, <a href="https://publications.waset.org/abstracts/search?q=Xu%20Jiadong"> Xu Jiadong</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Detection of malignant tumor inside the breast of women is a challenging field for the researchers. MWI (Microwave imaging) for breast cancer diagnosis has been of interest for last two decades, newly it suggested for finding cancerous tissues of women breast. A simple and basic idea of the mathematical modeling is used throughout this paper for imaging of malignant tumor. In this paper, the authors explained inverse scattering method in the microwave imaging and also present some simulation results. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=breast%20cancer%20detection" title="breast cancer detection">breast cancer detection</a>, <a href="https://publications.waset.org/abstracts/search?q=microwave%20imaging" title=" microwave imaging"> microwave imaging</a>, <a href="https://publications.waset.org/abstracts/search?q=tomography" title=" tomography"> tomography</a>, <a href="https://publications.waset.org/abstracts/search?q=tumor" title=" tumor"> tumor</a> </p> <a href="https://publications.waset.org/abstracts/2718/an-insight-into-early-stage-detection-of-malignant-tumor-by-microwave-imaging" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/2718.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">411</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">3723</span> Microwave Tomography: The Analytical Treatment for Detecting Malignant Tumor Inside Human Body</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Muhammad%20Hassan%20Khalil">Muhammad Hassan Khalil</a>, <a href="https://publications.waset.org/abstracts/search?q=Xu%20Jiadong"> Xu Jiadong</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Early detection through screening is the best tool short of a perfect treatment against the malignant tumor inside the breast of a woman. By detecting cancer in its early stages, it can be recognized and treated before it has the opportunity to spread and change into potentially dangerous. Microwave tomography is a new imaging method based on contrast in dielectric properties of materials. The mathematical theory of microwave tomography involves solving an inverse problem for Maxwell’s equations. In this paper, we present designed antenna for breast cancer detection, which will use in microwave tomography configuration. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=microwave%20imaging" title="microwave imaging">microwave imaging</a>, <a href="https://publications.waset.org/abstracts/search?q=inverse%20scattering" title=" inverse scattering"> inverse scattering</a>, <a href="https://publications.waset.org/abstracts/search?q=breast%20cancer" title=" breast cancer"> breast cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=malignant%20tumor%20detection" title=" malignant tumor detection"> malignant tumor detection</a> </p> <a href="https://publications.waset.org/abstracts/2719/microwave-tomography-the-analytical-treatment-for-detecting-malignant-tumor-inside-human-body" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/2719.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">371</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">3722</span> WT1 Exprassion in Malignant Surface Epithelial Ovarian Tumors</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Mahmoodreza%20Tahamtan">Mahmoodreza Tahamtan</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: Malignant surface epithelial ovarian tumors (SEOT) account for approximately 90% of primary ovarian cancer. Wilms tumor gene (WT1) product was defined as a tumor suppressor gene, but today it is considered capable of performing oncogenic functions. There seems to be differences in WT1 expression patterns among SEOT subtypes. We evaluate the immunohistochemical expression of WT1 protein among different histologic subtypes of SEOT. Materials and Methods: Immunohistochemistry for WT1 was done on 35 serous cystadenocarcinomas, 9 borderline serous tumors, 3 mucinous cystadenocarcinomas, 10 borderline mucinous tumors, 7 endometrioid ovarian carcinomas, 3 clear cell carcinomas, 1 malignant Brenner tumor, 2 metastatic adenocarcinomas, and 6 endometrial adenocarcinomas. A tumor was considered negative if < 1% of tumor cells were stained.Positive reactions were graded as follows:1+,1%-24%; 2+,25%-49%; 3+,50%-74%; 4+,75%-100%. Results: Of the 35 cases of ovarian serous cystadenocarcinoma, 30(85.7%) were diffusely positive (3+,4+),4 showed reactivity of < 50% of the tumor cells (1+,2+), and one were negative. All 9 borderline serous tumors showed immunoreactivity with WT1. All the mucinous tumors(n:13), endometrioid carcinomas (n: 7), clear cell carcinomas (n: 3), metastatic adenocarcinomas (n: 2) and primary endometrial carcinomas (n:6) were negative. The single malignant Brenner tumor showed a positive reaction for WT1(4+) Conclusion: WT1 is a good marker to distinguish primary ovarian serous carcinomas from other surface epithelial tumors (especially endometrioid subtype) and metastatic carcinomas (especially endometrial serous carcinoma), other than malignant mesothelioma. We cannot rely to the degree of expression inorder to separate high grade borderline serous tumors from low grade ones. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=WT1" title="WT1">WT1</a>, <a href="https://publications.waset.org/abstracts/search?q=ovary" title=" ovary"> ovary</a>, <a href="https://publications.waset.org/abstracts/search?q=epithelial%20tumors" title=" epithelial tumors"> epithelial tumors</a>, <a href="https://publications.waset.org/abstracts/search?q=malignant" title=" malignant"> malignant</a> </p> <a href="https://publications.waset.org/abstracts/159905/wt1-exprassion-in-malignant-surface-epithelial-ovarian-tumors" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/159905.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">103</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">3721</span> WT1 Expression in Ovarian Malignant Surface Epithelial Tumors</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Mahmoodreza%20Tahamtan">Mahmoodreza Tahamtan</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Malignant surface epithelial ovarian tumors(SEOT) account for approximately 90% of primary ovarian cancer. We evaluate the immunohistochemical expression of WT1 protein among different histologic subtypes of SEOT. Immunohistochemistry for WT1 was done on 35 serous cystadenocarcinomas, 9 borderline serous tumors. A tumor was considered negative if < 1% of tumor cells were stained.Positive reactions were graded as follows:1+,1%-24%; 2+,25%-49%; 3+,50%-74%; 4+,75%-100%. Of the 35 cases of ovarian serous cystadenocarcinoma 30(85.7%)were diffusely positive(3+,4+),4 showed reactivity of < 50% of the tumor cells(1+,2+) and one were negative. All 9 borderline serous tumors showed immunoreactivity with WT1. WT1 is a good marker to distinguish primary ovarian serous carcinomas from other surface epithelial tumors. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=WT1" title="WT1">WT1</a>, <a href="https://publications.waset.org/abstracts/search?q=ovary" title=" ovary"> ovary</a>, <a href="https://publications.waset.org/abstracts/search?q=malignant" title=" malignant"> malignant</a>, <a href="https://publications.waset.org/abstracts/search?q=epithelial%20tumors" title=" epithelial tumors"> epithelial tumors</a> </p> <a href="https://publications.waset.org/abstracts/160272/wt1-expression-in-ovarian-malignant-surface-epithelial-tumors" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/160272.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">102</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">3720</span> Efficacy and Safety of Uventa Metallic Stent for Malignant and Benign Ureteral Obstruction</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Deok%20Hyun%20Han">Deok Hyun Han</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Objective: To explore outcomes of UventaTM metallic ureteral stent between malignant and benign ureteral obstruction. Methods: We reviewed the medical records of 90 consecutive patients who underwent Uventa stent placement for benign or malignant ureteral obstruction from December 2009 to June 2013. We evaluated the clinical outcomes, complications, and reasons and results for unexpected stent removals. Results: The median follow-up was 10.7 (0.9 – 41) months. From a total of 125 ureter units, there were 24 units with benign obstructions and 101 units with malignant obstructions. Initial technical successes were achieved in all patients. The overall success rate was 70.8% with benign obstructions and 84.2% with malignant obstructions. The major reasons for treatment failure were stent migration (12.5%) in benign and tumor progression (11.9%) in malignant obstructions. The overall complication rate was similar between benign and malignant obstructions (58.3% and 42.6%), but severe complications, which are Clavien grade 3 or more, occurred in 41.7% of benign and 6.9% of malignant obstructions. The most common complications were stent migration (25.0%) in benign obstructions and persistent pain (14.9%) in malignant obstructions. The stent removal was done in 16 units; nine units that were removed by endoscopy and seven units were by open surgery. Conclusions: In malignant ureteral obstructions, the Uventa stent showed favorable outcomes with high success rate and acceptable complication rate. However, in benign ureteral obstructions, overall success rate and complication rate were less favorable. Malignant ureteral obstruction seems to be appropriate indication of Uventa stent placement. However, in chronic diffuse benign ureteral obstructions the decision of placement of Uventa stent has to be careful. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=cause" title="cause">cause</a>, <a href="https://publications.waset.org/abstracts/search?q=complication" title=" complication"> complication</a>, <a href="https://publications.waset.org/abstracts/search?q=ureteral%20obstruction" title=" ureteral obstruction"> ureteral obstruction</a>, <a href="https://publications.waset.org/abstracts/search?q=metal%20stent" title=" metal stent"> metal stent</a> </p> <a href="https://publications.waset.org/abstracts/83821/efficacy-and-safety-of-uventa-metallic-stent-for-malignant-and-benign-ureteral-obstruction" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/83821.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">203</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">3719</span> Recent Advancement in Dendrimer Based Nanotechnology for the Treatment of Brain Tumor</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Nitin%20Dwivedi">Nitin Dwivedi</a>, <a href="https://publications.waset.org/abstracts/search?q=Jigna%20Shah"> Jigna Shah</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Brain tumor is metastatic neoplasm of central nervous system, in most of cases it is life threatening disease with low survival rate. Despite of enormous efforts in the development of therapeutics and diagnostic tools, the treatment of brain tumors and gliomas remain a considerable challenge in the area of neuro-oncology. The most reason behind of this the presence of physiological barriers including blood brain barrier and blood brain tumor barrier, lead to insufficient reach ability of therapeutic agents at the site of tumor, result of inadequate destruction of gliomas. So there is an indeed need empowerment of brain tumor imaging for better characterization and delineation of tumors, visualization of malignant tissue during surgery, and tracking of response to chemotherapy and radiotherapy. Multifunctional different generations of dendrimer offer an improved effort for potentiate drug delivery at the site of brain tumor and gliomas. So this article emphasizes the innovative dendrimer approaches in tumor targeting, tumor imaging and delivery of therapeutic agent. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=blood%20brain%20barrier" title="blood brain barrier">blood brain barrier</a>, <a href="https://publications.waset.org/abstracts/search?q=dendrimer" title=" dendrimer"> dendrimer</a>, <a href="https://publications.waset.org/abstracts/search?q=gliomas" title=" gliomas"> gliomas</a>, <a href="https://publications.waset.org/abstracts/search?q=nanotechnology" title=" nanotechnology"> nanotechnology</a> </p> <a href="https://publications.waset.org/abstracts/30047/recent-advancement-in-dendrimer-based-nanotechnology-for-the-treatment-of-brain-tumor" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/30047.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">561</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">3718</span> Ancelim: Health System Restoration Protocol for Cancer Patients</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Mark%20Berry">Mark Berry</a> </p> <p class="card-text"><strong>Abstract:</strong></p> A number of studies have identified several factors involved in the malignant progression of cancer cells. The Primary modulator in driving inflammation to these transformed cells has been identified as the transcription factor known as nuclear factor-κB. This essential regulator of inflammation and the development of cancer, combined with a microenvironment of inflammation and signaling molecules, plays a major role in the malignant progression of cancer, and this progression is the result of the mutagenic predisposition of persistent substances that combat infection at tumor sites and other areas of chronic inflammation. Inflammation-induced tumors, and their inflammatory cells and regulators may be the primary source of metastasis of tumor cells through angiogenesis. Previous research on cytokines and chemokines, including their downstream targets, has been the focus of the cancer/inflammation connection. The identification of the biological mechanisms of other proteins vital to the inflammation cascade and their interactions are crucial to novel and effective therapeutic protocols for the treatment of inflammation-induced cancers. The Ancelim HSRP Protocol is just such a therapeutic intervention. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=ancelim" title="ancelim">ancelim</a>, <a href="https://publications.waset.org/abstracts/search?q=cancer" title=" cancer"> cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=inflammation" title=" inflammation"> inflammation</a>, <a href="https://publications.waset.org/abstracts/search?q=tumor" title=" tumor"> tumor</a> </p> <a href="https://publications.waset.org/abstracts/37512/ancelim-health-system-restoration-protocol-for-cancer-patients" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/37512.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">545</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">3717</span> Mature Cystic Teratomas of Ovary: A Series of 19 Cases with Rare Malignant Transformation in Three</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Parveen%20Kundu">Parveen Kundu</a>, <a href="https://publications.waset.org/abstracts/search?q=Nitika%20Chawla"> Nitika Chawla</a>, <a href="https://publications.waset.org/abstracts/search?q=Ruchi%20Agarwal"> Ruchi Agarwal</a>, <a href="https://publications.waset.org/abstracts/search?q=Swaran%20Kaur"> Swaran Kaur</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: Mature cystic teratoma is a benign, most common tumor of the ovary occurring mostly in young and middle-aged females. This study consists of 19 cases of mature cystic teratomas which were received in the Department Of Pathology over a period of two years. There were malignant transformations observed in three cases, which makes it very important for pathologists to thoroughly examine the entire specimen of mature cystic teratomas. Material and Methods: Nineteen reported cases of mature cystic teratomas were received in Deptt. Of Pathology, BPS GMC Khanpur Kalan, Sonepat, over a two-year period from November 2020 to October 2022 and reviewed retrospectively. Data regarding age, size, laterality, gross, morphological features, and surgery performed were retrieved from pathological archives. Results: In our study, the most common age of presentation was the 20-40 year age group. The most common presenting complaint was fullness in the abdomen or abdominal distension. Four out of 19 cases studied cases presented with bilateral ovarian cysts. Tumor size ranged from 6 to 20 cm in diameter. In seven cases, cysts were greater than or equal to 10 cm in diameter. Three cases showed malignant transformation. Conclusion: It is very important to thoroughly examine the contralateral ovary to rule out bilateral presentation. A furthermost thorough examination is advised in tumors of size >10 cm and in tumors with solid areas to rule out any malignant transformation. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=teratoma" title="teratoma">teratoma</a>, <a href="https://publications.waset.org/abstracts/search?q=ovary" title=" ovary"> ovary</a>, <a href="https://publications.waset.org/abstracts/search?q=malignant" title=" malignant"> malignant</a>, <a href="https://publications.waset.org/abstracts/search?q=transformation" title=" transformation"> transformation</a> </p> <a href="https://publications.waset.org/abstracts/169478/mature-cystic-teratomas-of-ovary-a-series-of-19-cases-with-rare-malignant-transformation-in-three" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/169478.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">87</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">3716</span> Malignant Ovarian Cancer Ascites Confers Platinum Chemoresistance to Ovarian Cancer Cells: A Combination Treatment with Crizotinib and 2 Hydroxyestradiol Restore Platinum Sensitivity</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Yifat%20Koren%20Carmi">Yifat Koren Carmi</a>, <a href="https://publications.waset.org/abstracts/search?q=Abed%20Agbarya"> Abed Agbarya</a>, <a href="https://publications.waset.org/abstracts/search?q=Hazem%20Khamaisi"> Hazem Khamaisi</a>, <a href="https://publications.waset.org/abstracts/search?q=Raymond%20Farah"> Raymond Farah</a>, <a href="https://publications.waset.org/abstracts/search?q=Yelena%20Shechtman"> Yelena Shechtman</a>, <a href="https://publications.waset.org/abstracts/search?q=Roman%20Korobochka"> Roman Korobochka</a>, <a href="https://publications.waset.org/abstracts/search?q=Jacob%20Gopas"> Jacob Gopas</a>, <a href="https://publications.waset.org/abstracts/search?q=Jamal%20Mahajna"> Jamal Mahajna</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Ovarian cancer (OC), the second most common form of gynecological malignancy, has a poor prognosis and is frequently identified in its late stages. The recommended treatment for OC typically includes a platinum-based chemotherapy, like carboplatin. Nonetheless, OC treatment has proven challenging due to toxicity and development of acquired resistance to therapy. Chemoresistance is a significant obstacle to a long-lasting response in OC patients, believed to arise from alterations within the cancer cells as well as within the tumor microenvironments (TME). Malignant ascites is a presenting feature in more than one-third of OC patients. It serves as a reservoir for a complex mixture of soluble factors, metabolites, and cellular components, providing a pro-inflammatory and tumor-promoting microenvironment for the OC cells. Malignant ascites is also associated with metastasis and chemoresistance. In an attempt to elucidate the role of TME in chemoresistance of OC, we monitored the ability of soluble factors derived from ascites fluids to affect platinum sensitivity of OC cells. This research, compared ascites fluids from non-malignant cirrhotic patients to those from OC patients in terms of their ability to alter the platinum sensitivity of OC cells. Our findings indicated that exposure to OC ascites induces platinum chemoresistance on OC cells in 11 out of 13 cases (85%). In contrast, 75% of cirrhosis ascites (3 out of 4) failed to confer platinum chemoresistance to OC cells. Cytokine array analysis revealed that IL-6, and to a lesser extent HGF were enriched in OC ascites, whereas IL-22 was enriched in cirrhosis ascites. Pharmaceutical inhibitors that target the IL-6/JAK signaling pathway were mildly effective in overcoming the platinum chemoresistance induced by malignant ascites. In contrast, Crizotinib an HGF/c-MET inhibitor, and 2-hydroxyestradiol (2HE2) were effective in restoring platinum chemoresistance to OC. Our findings demonstrate the importance of OC ascites in supporting platinum chemoresistance as well as the potential of a combination therapy with Crizotinib and the estradiol metabolite 2HE2 to regain OC cells chemosensitivity. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=ovarian%20cancer" title="ovarian cancer">ovarian cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=platinum%20chemoresistance" title=" platinum chemoresistance"> platinum chemoresistance</a>, <a href="https://publications.waset.org/abstracts/search?q=malignant%20ascites" title=" malignant ascites"> malignant ascites</a>, <a href="https://publications.waset.org/abstracts/search?q=tumor%20microenvironment" title=" tumor microenvironment"> tumor microenvironment</a>, <a href="https://publications.waset.org/abstracts/search?q=IL-6" title=" IL-6"> IL-6</a>, <a href="https://publications.waset.org/abstracts/search?q=2-hydroxyestradiol" title=" 2-hydroxyestradiol"> 2-hydroxyestradiol</a>, <a href="https://publications.waset.org/abstracts/search?q=HGF" title=" HGF"> HGF</a>, <a href="https://publications.waset.org/abstracts/search?q=crizotinib" title=" crizotinib"> crizotinib</a> </p> <a href="https://publications.waset.org/abstracts/170418/malignant-ovarian-cancer-ascites-confers-platinum-chemoresistance-to-ovarian-cancer-cells-a-combination-treatment-with-crizotinib-and-2-hydroxyestradiol-restore-platinum-sensitivity" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/170418.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">69</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">3715</span> Epidemiology of Cutaneous Malignant Melanoma in Pakistan: Incidence, Clinical Subtypes, Tumor Stage and Localization</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Warda%20Jabeen">Warda Jabeen</a>, <a href="https://publications.waset.org/abstracts/search?q=Romaisa%20Shamim%20Khan"> Romaisa Shamim Khan</a>, <a href="https://publications.waset.org/abstracts/search?q=Osama%20Shakeel"> Osama Shakeel</a>, <a href="https://publications.waset.org/abstracts/search?q=Ahmed%20Faraz%20Bhatti"> Ahmed Faraz Bhatti</a>, <a href="https://publications.waset.org/abstracts/search?q=Raza%20Hussain"> Raza Hussain</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: The worldwide incidence of cutaneous melanoma (CM) has been on the rise over the past few decades. Primary prevention and early treatment remain the focus of management to reduce the burden of disease. This entails identification of risk factors to prompt early diagnosis. In Pakistan, there is a scarcity of clinico-pathological data relating to cutaneous malignant melanoma. Objective: The purpose of this study was to analyze the epidemiological and clinical characteristics of patients presenting with cutaneous malignant melanoma in Pakistan, and to compare the results with other studies. Method: Shaukat Khanum Memorial Cancer Hospital and Research Centre is currently the only dedicated cancer hospital in the country, accepting patients from all over Pakistan. Majority of the patients, however, belong to the northern half of the country. From the recorded data of the hospital, all cutaneous melanoma cases were identified and evaluated. Results: Between 1997 and 2017, a total of 169 cutaneous melanoma patients were registered at Shaukat Khanum. Mean age was 47.5 years. The highest incidence of melanoma was seen in the age group 40-59 years (n=69, 40.8%). Most commonly reported clinical subtype was unspecified melanoma (n=154, 91%). Amongst those in which T stage was reported, the most frequently observed T-stage at presentation was T4 (n=23, 13.6%). With regards to body distribution, in our study CM was seen most commonly in the lower limb including the hip. The yearly incidence of melanoma has increased/remained stable from 2007 to 2017. Conclusion: cutaneous malignant melanoma is a fairly common disease in Pakistan. Patients tend to present at a more advanced stage as compared to patients in developed countries. Identification of risk factors and tumor characteristics is therefore of paramount importance to deal with these patients. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=epidemiology%20of%20cutaneous%20malignant%20melanoma" title="epidemiology of cutaneous malignant melanoma">epidemiology of cutaneous malignant melanoma</a>, <a href="https://publications.waset.org/abstracts/search?q=cutaneous%20malignant%20melanoma" title=" cutaneous malignant melanoma"> cutaneous malignant melanoma</a>, <a href="https://publications.waset.org/abstracts/search?q=Pakistan" title=" Pakistan"> Pakistan</a>, <a href="https://publications.waset.org/abstracts/search?q=skin%20cancer" title=" skin cancer"> skin cancer</a> </p> <a href="https://publications.waset.org/abstracts/101508/epidemiology-of-cutaneous-malignant-melanoma-in-pakistan-incidence-clinical-subtypes-tumor-stage-and-localization" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/101508.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">136</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">3714</span> Collision Tumor of Plasmacytoma with Hematological and Non-Hematological Malignancies</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Arati%20Inamdar">Arati Inamdar</a>, <a href="https://publications.waset.org/abstracts/search?q=Siddharth%20Bhattacharyya"> Siddharth Bhattacharyya</a>, <a href="https://publications.waset.org/abstracts/search?q=Kester%20Haye"> Kester Haye</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Collision tumors are rare entities characterized by neoplasms of two different cell populations with distinct separating boundaries. Such tumors could be benign, malignant, or a combination of both. The exact mechanism of origin for collision tumors is predicted to be tumor heterogeneity or concurrent occurrence of neoplasm in the same organ. We present two cases of plasmacytoma presenting as a collision tumor, one with a tumor of hematological origin and another with a non-hematological origin, namely Chronic Lymphocytic Leukemia and Adenocarcinoma of the colon, respectively. The immunohistochemical stains and flowcytometry analysis performed on the specimens aided incorrect diagnosis. Interestingly, neoplastic cells of plasmacytoma in the first case demonstrated strong cytokeratin along with weak Epithelial Specific Antigen/ Epithelial cell adhesion molecule Monoclonal Antibody (MOC31) positivity, indicating that the tumor may influence the microenvironment of the tumor in the vicinity. Furthermore, the next-generation sequencing studies performed on the specimen with plasmacytoma and chronic lymphocytic lymphoma demonstrated BReast CAncer gene (BRCA2) and Tumor Necrosis Factor Alpha Induced Protein 3 (TNFAIP3) as a disease associated variants suggestive of risk for multiple tumors including collision tumors. Our reports highlight the unique collision tumors involving plasmacytoma, which have never been reported previously, as well as provide necessary insights about the underline genetic aberrations and tumor heterogeneity through sequencing studies and allow clonality assessment for subsequent tumors. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=BRCA2" title="BRCA2">BRCA2</a>, <a href="https://publications.waset.org/abstracts/search?q=collision%20tumor" title=" collision tumor"> collision tumor</a>, <a href="https://publications.waset.org/abstracts/search?q=chronic%20lymphocytic%20leukemia" title=" chronic lymphocytic leukemia"> chronic lymphocytic leukemia</a>, <a href="https://publications.waset.org/abstracts/search?q=plasmacytoma" title=" plasmacytoma"> plasmacytoma</a> </p> <a href="https://publications.waset.org/abstracts/162721/collision-tumor-of-plasmacytoma-with-hematological-and-non-hematological-malignancies" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/162721.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">190</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">3713</span> Reliability of Diffusion Tensor Imaging in Differentiation of Salivary Gland Tumors</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Sally%20Salah%20El%20Menshawy">Sally Salah El Menshawy</a>, <a href="https://publications.waset.org/abstracts/search?q=Ghada%20M.%20Ahmed%20GabAllah"> Ghada M. Ahmed GabAllah</a>, <a href="https://publications.waset.org/abstracts/search?q=Doaa%20Khedr%20M.%20Khedr"> Doaa Khedr M. Khedr</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: Our study aims to detect the diagnostic role of DTI in the differentiation of salivary glands benign and malignant lesions. Results: Our study included 50 patients (25males and 25 females) divided into 4 groups (benign lesions n=20, malignant tumors n=13, post-operative changes n=10 and normal n=7). 28 patients were with parotid gland lesions, 4 patients were with submandibular gland lesions and only 1 case with sublingual gland affection. The mean fractional anisotropy (FA) and apparent diffusion coefficient (ADC) of malignant salivary gland tumors (n = 13) (0.380±0.082 and 0.877±0.234× 10⁻³ mm² s⁻¹) were significantly different (P<0.001) than that of benign tumors (n = 20) (0.147±0.03 and 1.47±0.605 × 10⁻³ mm² s⁻¹), respectively. The mean FA and ADC of post-operative changes (n = 10) were (0.211±0.069 and 1.63±0.20× 10⁻³ mm² s⁻¹) while that of normal glands (n =7) was (0.251±0.034and 1.54±0.29× 10⁻³ mm² s⁻¹), respectively. Using ADC to differentiate malignant lesions from benign lesions has an (AUC) of 0.810, with an accuracy of 69.7%. ADC used to differentiate malignant lesions from post-operative changes has (AUC) of 1.0, and an accuracy of 95.7%. FA used to discriminate malignant from benign lesions has (AUC) of 1.0, and an accuracy of 93.9%. FA used to differentiate malignant from post-operative changes has (AUC) of 0.923, and an accuracy of 95.7%. Combined FA and ADC used to differentiate malignant from benign lesions has (AUC) of 1.0, and an accuracy of 100%. Combined FA and ADC used to differentiate malignant from post-operative changes has (AUC) of 1.0, and an accuracy of 100%. Conclusion: Combined FA and ADC can differentiate malignant tumors from benign salivary gland lesions. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=diffusion%20tensor%20imaging" title="diffusion tensor imaging">diffusion tensor imaging</a>, <a href="https://publications.waset.org/abstracts/search?q=MRI" title=" MRI"> MRI</a>, <a href="https://publications.waset.org/abstracts/search?q=salivary%20gland" title=" salivary gland"> salivary gland</a>, <a href="https://publications.waset.org/abstracts/search?q=tumors" title=" tumors"> tumors</a> </p> <a href="https://publications.waset.org/abstracts/154784/reliability-of-diffusion-tensor-imaging-in-differentiation-of-salivary-gland-tumors" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/154784.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">111</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">3712</span> Computer-Aided Diagnosis System Based on Multiple Quantitative Magnetic Resonance Imaging Features in the Classification of Brain Tumor</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Chih%20Jou%20Hsiao">Chih Jou Hsiao</a>, <a href="https://publications.waset.org/abstracts/search?q=Chung%20Ming%20Lo"> Chung Ming Lo</a>, <a href="https://publications.waset.org/abstracts/search?q=Li%20Chun%20Hsieh"> Li Chun Hsieh</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Brain tumor is not the cancer having high incidence rate, but its high mortality rate and poor prognosis still make it as a big concern. On clinical examination, the grading of brain tumors depends on pathological features. However, there are some weak points of histopathological analysis which can cause misgrading. For example, the interpretations can be various without a well-known definition. Furthermore, the heterogeneity of malignant tumors is a challenge to extract meaningful tissues under surgical biopsy. With the development of magnetic resonance imaging (MRI), tumor grading can be accomplished by a noninvasive procedure. To improve the diagnostic accuracy further, this study proposed a computer-aided diagnosis (CAD) system based on MRI features to provide suggestions of tumor grading. Gliomas are the most common type of malignant brain tumors (about 70%). This study collected 34 glioblastomas (GBMs) and 73 lower-grade gliomas (LGGs) from The Cancer Imaging Archive. After defining the region-of-interests in MRI images, multiple quantitative morphological features such as region perimeter, region area, compactness, the mean and standard deviation of the normalized radial length, and moment features were extracted from the tumors for classification. As results, two of five morphological features and three of four image moment features achieved p values of <0.001, and the remaining moment feature had p value <0.05. Performance of the CAD system using the combination of all features achieved the accuracy of 83.18% in classifying the gliomas into LGG and GBM. The sensitivity is 70.59% and the specificity is 89.04%. The proposed system can become a second viewer on clinical examinations for radiologists. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=brain%20tumor" title="brain tumor">brain tumor</a>, <a href="https://publications.waset.org/abstracts/search?q=computer-aided%20diagnosis" title=" computer-aided diagnosis"> computer-aided diagnosis</a>, <a href="https://publications.waset.org/abstracts/search?q=gliomas" title=" gliomas"> gliomas</a>, <a href="https://publications.waset.org/abstracts/search?q=magnetic%20resonance%20imaging" title=" magnetic resonance imaging"> magnetic resonance imaging</a> </p> <a href="https://publications.waset.org/abstracts/70083/computer-aided-diagnosis-system-based-on-multiple-quantitative-magnetic-resonance-imaging-features-in-the-classification-of-brain-tumor" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/70083.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">260</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">3711</span> Undifferentiated Embryonal Sarcoma of Liver: A Rare Case Report</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Thieu-Thi%20Tra%20My">Thieu-Thi Tra My</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Undifferentiated embryonal sarcoma of the liver (UESL), a rare malignant mesenchymal tumor, is commonly seen in children. The symptoms and imaging were not specific, so it could be mimicked with other tumors or liver abscesses. The tumor often appears as a large heterogeneous echoic solid mass with small cystic areas while showing a cyst-like appearance on CT and MRI. The histopathological manifestation of the UESL consisted of stellate-shaped and spindle cells scattered on a myxoid background with high mitotic count. Cells with multiple or bizarre nuclear were also observed. Here, we aimed to describe a 9-year-old male diagnosed with UESL focused on imaging and histopathological characteristics. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=undifferentiated%20embryonal%20sarcoma%20of%20liver" title="undifferentiated embryonal sarcoma of liver">undifferentiated embryonal sarcoma of liver</a>, <a href="https://publications.waset.org/abstracts/search?q=UESL" title=" UESL"> UESL</a>, <a href="https://publications.waset.org/abstracts/search?q=liver%20sarcoma" title=" liver sarcoma"> liver sarcoma</a>, <a href="https://publications.waset.org/abstracts/search?q=liver%20tumor" title=" liver tumor"> liver tumor</a>, <a href="https://publications.waset.org/abstracts/search?q=children" title=" children"> children</a> </p> <a href="https://publications.waset.org/abstracts/170077/undifferentiated-embryonal-sarcoma-of-liver-a-rare-case-report" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/170077.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">74</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">3710</span> Clonal Evaluation of Malignant Mesothelioma</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Sabahattin%20Comertpay">Sabahattin Comertpay</a>, <a href="https://publications.waset.org/abstracts/search?q=Sandra%20Pastorino"> Sandra Pastorino</a>, <a href="https://publications.waset.org/abstracts/search?q=Rosanna%20Mezzapelle"> Rosanna Mezzapelle</a>, <a href="https://publications.waset.org/abstracts/search?q=Mika%20Tanji"> Mika Tanji</a>, <a href="https://publications.waset.org/abstracts/search?q=Oriana%20Strianese"> Oriana Strianese</a>, <a href="https://publications.waset.org/abstracts/search?q=Andrea%20Napolitano"> Andrea Napolitano</a>, <a href="https://publications.waset.org/abstracts/search?q=Tracey%20Weigel"> Tracey Weigel</a>, <a href="https://publications.waset.org/abstracts/search?q=Joseph%20Friedberg"> Joseph Friedberg</a>, <a href="https://publications.waset.org/abstracts/search?q=Paul%20Sugarbaker"> Paul Sugarbaker</a>, <a href="https://publications.waset.org/abstracts/search?q=Thomas%20Krausz"> Thomas Krausz</a>, <a href="https://publications.waset.org/abstracts/search?q=Ena%20Wang"> Ena Wang</a>, <a href="https://publications.waset.org/abstracts/search?q=Amy%20Powers"> Amy Powers</a>, <a href="https://publications.waset.org/abstracts/search?q=Giovanni%20Gaudino"> Giovanni Gaudino</a>, <a href="https://publications.waset.org/abstracts/search?q=Harvey%20I.%20Pass"> Harvey I. Pass</a>, <a href="https://publications.waset.org/abstracts/search?q=Fatmagul%20Ozcelik"> Fatmagul Ozcelik</a>, <a href="https://publications.waset.org/abstracts/search?q=Barbara%20L.%20Parsons"> Barbara L. Parsons</a>, <a href="https://publications.waset.org/abstracts/search?q=Haining%20Yang"> Haining Yang</a>, <a href="https://publications.waset.org/abstracts/search?q=Michele%20Carbone"> Michele Carbone</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Tumors are thought to be monoclonal in origin. This paradigm arose decades ago, primarily from the study of hematopoietic malignancies and sarcomas. The clonal origin of malignant mesothelioma (MM), a deadly cancer resistant to the current therapies, has not been investigated. Examination of the pleura from patients with MM shows often the presence of multiple pleural nodules, raising the question of whether they represent independent or metastatic growth processes. To investigate the clonality patterns of MM, we used the HUMARA (Human Androgen Receptor) assay to examine 14 sporadic and 2 familial Malignant Mesotheliomas (MM). Of 16 specimens studied, 15 were informative and 14/15 revealed two electrophoretically distinct methylated HUMARA alleles, indicating a polyclonal origin for these tumors. This discovery has important clinical implications, because an accurate assessment of tumor clonality is key to the design of novel molecular strategies for the treatment of MM. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=malignant%20mesothelioma" title="malignant mesothelioma">malignant mesothelioma</a>, <a href="https://publications.waset.org/abstracts/search?q=clonal%20origin" title=" clonal origin"> clonal origin</a>, <a href="https://publications.waset.org/abstracts/search?q=HUMARA" title=" HUMARA"> HUMARA</a>, <a href="https://publications.waset.org/abstracts/search?q=sarcomas" title=" sarcomas"> sarcomas</a> </p> <a href="https://publications.waset.org/abstracts/14879/clonal-evaluation-of-malignant-mesothelioma" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/14879.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">458</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">3709</span> A Wearable Fluorescence Imaging Device for Intraoperative Identification of Human Brain Tumors</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Guoqiang%20Yu">Guoqiang Yu</a>, <a href="https://publications.waset.org/abstracts/search?q=Mehrana%20Mohtasebi"> Mehrana Mohtasebi</a>, <a href="https://publications.waset.org/abstracts/search?q=Jinghong%20Sun"> Jinghong Sun</a>, <a href="https://publications.waset.org/abstracts/search?q=Thomas%20Pittman"> Thomas Pittman</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Malignant glioma (MG) is the most common type of primary malignant brain tumor. Surgical resection of MG remains the cornerstone of therapy, and the extent of resection correlates with patient survival. A limiting factor for resection, however, is the difficulty in differentiating the tumor from normal tissue during surgery. Fluorescence imaging is an emerging technique for real-time intraoperative visualization of MGs and their boundaries. However, most clinical-grade neurosurgical operative microscopes with fluorescence imaging ability are hampered by low adoption rates due to high cost, limited portability, limited operation flexibility, and lack of skilled professionals with technical knowledge. To overcome the limitations, we innovatively integrated miniaturized light sources, flippable filters, and a recording camera to the surgical eye loupes to generate a wearable fluorescence eye loupe (FLoupe) device for intraoperative imaging of fluorescent MGs. Two FLoupe prototypes were constructed for imaging of Fluorescein and 5-aminolevulinic acid (5-ALA), respectively. The wearable FLoupe devices were tested on tumor-simulating phantoms and patients with MGs. Comparable results were observed against the standard neurosurgical operative microscope (PENTERO® 900) with fluorescence kits. The affordable and wearable FLoupe devices enable visualization of both color and fluorescence images with the same quality as the large and expensive stationary operative microscopes. The wearable FLoupe device allows for a greater range of movement, less obstruction, and faster/easier operation. Thus, it reduces surgery time and is more easily adapted to the surgical environment than unwieldy neurosurgical operative microscopes. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=fluorescence%20guided%20surgery" title="fluorescence guided surgery">fluorescence guided surgery</a>, <a href="https://publications.waset.org/abstracts/search?q=malignant%20glioma" title=" malignant glioma"> malignant glioma</a>, <a href="https://publications.waset.org/abstracts/search?q=neurosurgical%20operative%20microscope" title=" neurosurgical operative microscope"> neurosurgical operative microscope</a>, <a href="https://publications.waset.org/abstracts/search?q=wearable%20fluorescence%20imaging%20device" title=" wearable fluorescence imaging device"> wearable fluorescence imaging device</a> </p> <a href="https://publications.waset.org/abstracts/179790/a-wearable-fluorescence-imaging-device-for-intraoperative-identification-of-human-brain-tumors" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/179790.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">66</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">3708</span> The Epigenetic Background Depended Treatment Planning for Glioblastoma Multiforme</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Rasime%20Kalkan">Rasime Kalkan</a>, <a href="https://publications.waset.org/abstracts/search?q=Emine%20Ikbal%20Atli"> Emine Ikbal Atli</a>, <a href="https://publications.waset.org/abstracts/search?q=Ali%20Arslanta%C5%9F"> Ali Arslantaş</a>, <a href="https://publications.waset.org/abstracts/search?q=Muhsin%20%C3%96zdemir"> Muhsin Özdemir</a>, <a href="https://publications.waset.org/abstracts/search?q=Sevilhan%20Artan"> Sevilhan Artan</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Glioblastoma (WHO grade IV), is the malignant form of brain tumor, the genetic background of the GBM is highly variable. The tumor mass of a GBM is multilayered and every tumor layer shows distinct characteristics with a different cell population. The treatment planning of GBM should be focused on the tumor genetic characteristics. We screened primary glioblastoma multiforme (GBM) in a population-based study for MGMT and RARβ methylation and IDH1 mutation correlated them with clinical data and treatment. There was no correlation between MGMT-promoter methylation and overall survival. The overall survival time of the patients with methylated RARβ was statically (OS;p<0,05) significance between the patients who were treated with chemotherapy and radiotherapy. Here we showed the status of IDH1 gene associatied with younger age. We demonstrated that the together with MGMT gene the RARβ gene should be used as a potantial treatment decision marker for GBMs. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=RAR%CE%B2" title="RARβ">RARβ</a>, <a href="https://publications.waset.org/abstracts/search?q=primary%20glioblastoma%20multiforme" title=" primary glioblastoma multiforme"> primary glioblastoma multiforme</a>, <a href="https://publications.waset.org/abstracts/search?q=methylation" title=" methylation"> methylation</a>, <a href="https://publications.waset.org/abstracts/search?q=MGMT" title=" MGMT"> MGMT</a> </p> <a href="https://publications.waset.org/abstracts/66871/the-epigenetic-background-depended-treatment-planning-for-glioblastoma-multiforme" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/66871.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">345</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">3707</span> Discriminant Function Based on Circulating Tumor Cells for Accurate Diagnosis of Metastatic Breast Cancer</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Hatem%20A.%20El-Mezayen">Hatem A. El-Mezayen</a>, <a href="https://publications.waset.org/abstracts/search?q=Ahmed%20Abdelmajeed"> Ahmed Abdelmajeed</a>, <a href="https://publications.waset.org/abstracts/search?q=Fatehya%20Metwally"> Fatehya Metwally</a>, <a href="https://publications.waset.org/abstracts/search?q=Usama%20Elsaly"> Usama Elsaly</a>, <a href="https://publications.waset.org/abstracts/search?q=Salwa%20Atef"> Salwa Atef</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Tumor metastasis involves the dissemination of malignant cells into the basement membrane and vascular system contributes to the circulating pool of these markers. In this context our aim has been focused on development of a non-invasive. Circulating tumor cells (CTCs) represent a unique liquid biopsy carrying comprehensive biological information of the primary tumor. Herein, we sought to develop a novel score based on the combination of the most significant CTCs biomarkers with and routine laboratory tests for accurate detection of metastatic breast cancer. Methods: Cytokeratin 18 (CK18), Cytokeratin 19 (CK19), and CA15.3 were assayed in metastatic breast cancer (MBC) patients (75), non-MBC patients (50) and healthy control (20). Results: Areas under receiving operating curve (AUCs) were calculated and used for construction on novel score. A novel score named MBC-CTCs = CA15.3 (U/L) × 0.08 + CK 18 % × 2.9 + CK19 × 3.1– 510. That function correctly classified 87% of metastatic breast cancer at cut-off value = 0.55. (i.e great than 0.55 indicates patients with metastatic breast cancer and less than 0.55 indicates patients with non-metastatic breast cancer). Conclusion: MBC-CTCs is a novel, non-invasive and simple can applied to discriminate patients with metastatic breast cancer. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=metastatic%20breast%20cancer" title="metastatic breast cancer">metastatic breast cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=circulating%20tumor%20cells" title=" circulating tumor cells"> circulating tumor cells</a>, <a href="https://publications.waset.org/abstracts/search?q=cytokeratin" title=" cytokeratin"> cytokeratin</a>, <a href="https://publications.waset.org/abstracts/search?q=EpiCam" title=" EpiCam"> EpiCam</a> </p> <a href="https://publications.waset.org/abstracts/146716/discriminant-function-based-on-circulating-tumor-cells-for-accurate-diagnosis-of-metastatic-breast-cancer" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/146716.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">214</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">3706</span> Role of Human Epididymis Protein 4 as a Biomarker in the Diagnosis of Ovarian Cancer</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Amar%20Ranjan">Amar Ranjan</a>, <a href="https://publications.waset.org/abstracts/search?q=Julieana%20Durai"> Julieana Durai</a>, <a href="https://publications.waset.org/abstracts/search?q=Pranay%20Tanwar"> Pranay Tanwar</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background &Introduction: Ovarian cancer is one of the most common malignant tumor in the female. 70% of the cases of ovarian cancer are diagnosed at an advanced stage. The five-year survival rate associated with ovarian cancer is less than 30%. The early diagnosis of ovarian cancer becomes a key factor in improving the survival rate of patients. Presently, CAl25 (carbohydrate antigen125) is used for the diagnosis and therapeutic monitoring of ovarian cancer, but its sensitivity and specificity is not ideal. The introduction of HE4, human epididymis protein 4 has attracted much attention. HE4 has a sensitivity and specificity of 72.9% and 95% for differentiating between benign and malignant adnexal masses, which is better than CA125 detection. Methods: Serum HE4 and CA -125 were estimated using the chemiluminescence method. Our cases were 40 epithelial ovarian cancer, 9 benign ovarian tumor, 29 benign gynaecological diseases and 13 healthy individuals. This group include healthy woman those who have undergoing family planning and menopause-related medical consultations and they are negative for ovarian mass. Optimal cut off values for HE4 and CA125 were 55.89pmol/L and 40.25U/L respectively (determined by statistical analysis). Results: The level of HE4 was raised in all ovarian cancer patients (n=40) whereas CA125 levels were normal in 6/40 ovarian cancer patients, which were the cases of OC confirmed by histopathology. There is a significant decrease in the level of HE4 with comparison to CA125 in benign ovarian tumor cases. Both the levels of HE4 and CA125 were raised in the nonovarian cancer group, which includes cancer of endometrium and cervix. In the healthy group, HE4 was normal in all patients except in one case of the rudimentary horn, and the reason for this raised HE4 level is due to the incomplete development of uterus whereas CA125 was raised in 3 cases. Conclusions: Findings showed that the serum level of HE4 is an important indicator in the diagnosis of ovarian cancer, and it also distinguishes between benign and malignant pelvic masses. However, a combination of HE4 and CA125 panel will be extremely valuable in improving the diagnostic efficiency of ovarian cancer. These findings of our study need to be validated in the larger cohort of patients. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=human%20epididymis%20protein%204" title="human epididymis protein 4">human epididymis protein 4</a>, <a href="https://publications.waset.org/abstracts/search?q=ovarian%20cancer" title=" ovarian cancer"> ovarian cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=diagnosis" title=" diagnosis"> diagnosis</a>, <a href="https://publications.waset.org/abstracts/search?q=benign%20lesions" title=" benign lesions"> benign lesions</a> </p> <a href="https://publications.waset.org/abstracts/108113/role-of-human-epididymis-protein-4-as-a-biomarker-in-the-diagnosis-of-ovarian-cancer" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/108113.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">131</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">3705</span> Nanomechanical Characterization of Healthy and Tumor Lung Tissues at Cell and Extracellular Matrix Level</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Valeria%20Panzetta">Valeria Panzetta</a>, <a href="https://publications.waset.org/abstracts/search?q=Ida%20Musella"> Ida Musella</a>, <a href="https://publications.waset.org/abstracts/search?q=Sabato%20Fusco"> Sabato Fusco</a>, <a href="https://publications.waset.org/abstracts/search?q=Paolo%20Antonio%20Netti"> Paolo Antonio Netti</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The study of the biophysics of living cells drew attention to the pivotal role of the cytoskeleton in many cell functions, such as mechanics, adhesion, proliferation, migration, differentiation and neoplastic transformation. In particular, during the complex process of malignant transformation and invasion cell cytoskeleton devolves from a rigid and organized structure to a more compliant state, which confers to the cancer cells a great ability to migrate and adapt to the extracellular environment. In order to better understand the malignant transformation process from a mechanical point of view, it is necessary to evaluate the direct crosstalk between the cells and their surrounding extracellular matrix (ECM) in a context which is close to in vivo conditions. In this study, human biopsy tissues of lung adenocarcinoma were analyzed in order to define their mechanical phenotype at cell and ECM level, by using particle tracking microrheology (PTM) technique. Polystyrene beads (500 nm) were introduced into the sample slice. The motion of beads was obtained by tracking their displacements across cell cytoskeleton and ECM structures and mean squared displacements (MSDs) were calculated from bead trajectories. It has been already demonstrated that the amplitude of MSD is inversely related to the mechanical properties of intracellular and extracellular microenvironment. For this reason, MSDs of particles introduced in cytoplasm and ECM of healthy and tumor tissues were compared. PTM analyses showed that cancerous transformation compromises mechanical integrity of cells and extracellular matrix. In particular, the MSD amplitudes in cells of adenocarcinoma were greater as compared to cells of normal tissues. The increased motion is probably associated to a less structured cytoskeleton and consequently to an increase of deformability of cells. Further, cancer transformation is also accompanied by extracellular matrix stiffening, as confirmed by the decrease of MSDs of matrix in tumor tissue, a process that promotes tumor proliferation and invasiveness, by activating typical oncogenic signaling pathways. In addition, a clear correlation between MSDs of cells and tumor grade was found. MSDs increase when tumor grade passes from 2 to 3, indicating that cells undergo to a trans-differentiation process during tumor progression. ECM stiffening is not dependent on tumor grade, but the tumor stage resulted to be strictly correlated with both cells and ECM mechanical properties. In fact, a greater stage is assigned to tumor spread to regional lymph nodes and characterized by an up-regulation of different ECM proteins, such as collagen I fibers. These results indicate that PTM can be used to get nanomechanical characterization at different scale levels in an interpretative and diagnostic context. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=cytoskeleton" title="cytoskeleton">cytoskeleton</a>, <a href="https://publications.waset.org/abstracts/search?q=extracellular%20matrix" title=" extracellular matrix"> extracellular matrix</a>, <a href="https://publications.waset.org/abstracts/search?q=mechanical%20properties" title=" mechanical properties"> mechanical properties</a>, <a href="https://publications.waset.org/abstracts/search?q=particle%20tracking%20microrheology" title=" particle tracking microrheology"> particle tracking microrheology</a>, <a href="https://publications.waset.org/abstracts/search?q=tumor" title=" tumor"> tumor</a> </p> <a href="https://publications.waset.org/abstracts/57656/nanomechanical-characterization-of-healthy-and-tumor-lung-tissues-at-cell-and-extracellular-matrix-level" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/57656.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">280</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">3704</span> PCR Based DNA Analysis in Detecting P53 Mutation in Human Breast Cancer (MDA-468)</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Debbarma%20Asis">Debbarma Asis</a>, <a href="https://publications.waset.org/abstracts/search?q=Guha%20Chandan"> Guha Chandan</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Tumor Protein-53 (P53) is one of the tumor suppressor proteins. P53 regulates the cell cycle that conserves stability by preventing genome mutation. It is named so as it runs as 53-kilodalton (kDa) protein on Polyacrylamide gel electrophoresis although the actual mass is 43.7 kDa. Experimental evidence has indicated that P53 cancer mutants loses tumor suppression activity and subsequently gain oncogenic activities to promote tumourigenesis. Tumor-specific DNA has recently been detected in the plasma of breast cancer patients. Detection of tumor-specific genetic materials in cancer patients may provide a unique and valuable tumor marker for diagnosis and prognosis. Commercially available MDA-468 breast cancer cell line was used for the proposed study. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=tumor%20protein%20%28P53%29" title="tumor protein (P53)">tumor protein (P53)</a>, <a href="https://publications.waset.org/abstracts/search?q=cancer%20mutants" title=" cancer mutants"> cancer mutants</a>, <a href="https://publications.waset.org/abstracts/search?q=MDA-468" title=" MDA-468"> MDA-468</a>, <a href="https://publications.waset.org/abstracts/search?q=tumor%20suppressor%20gene" title=" tumor suppressor gene"> tumor suppressor gene</a> </p> <a href="https://publications.waset.org/abstracts/43690/pcr-based-dna-analysis-in-detecting-p53-mutation-in-human-breast-cancer-mda-468" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/43690.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">480</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">3703</span> Prognosis, Clinical Outcomes and Short Term Survival Analyses of Patients with Cutaneous Melanomas</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Osama%20Shakeel">Osama Shakeel</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The objective of the paper is to study the clinic-pathological factors, survival analyses, recurrence rate, metastatic rate, risk factors and the management of cutaneous malignant melanoma at Shaukat Khanum Memorial Cancer Hospital and Research Center. Methodology: From 2014 to 2017, all patients with a diagnosis of cutaneous malignant melanoma (CMM) were included in the study. Demographic variables were collected. Short and long term oncological outcomes were recorded. All data were entered and analyzed in SPSS version 21. Results: A total of 28 patients were included in the study. Median age was 46.5 +/-15.9 years. There were 16 male and 12 female patients. The family history of melanoma was present in 7.1% (n=2) of the patients. All patients had a mean survival of 13.43+/- 9.09 months. Lower limb was the commonest site among all which constitutes 46.4%(n=13). On histopathological analyses, ulceration was seen in 53.6% (n=15) patients. Unclassified tumor type was present in 75%(n=21) of the patients followed by nodular 21.4% (n=6) and superficial spreading 3.5%(n=1). Clark level IV was the commonest presentation constituting 46.4%(n=13). Metastases were seen in 50%(n=14) of the patients. Local recurrence was observed in 60.7%(n=17). 64.3%(n=18) lived after one year of treatment. Conclusion: CMM is a fatal disease. Although its disease of fair skin individuals, however, the incidence of CMM is also rising in this part of the world. Management includes early diagnoses and prompt management. However, mortality associated with this disease is still not favorable. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=malignant%20cancer%20of%20skin" title="malignant cancer of skin">malignant cancer of skin</a>, <a href="https://publications.waset.org/abstracts/search?q=cutaneous%20malignant%20melanoma" title=" cutaneous malignant melanoma"> cutaneous malignant melanoma</a>, <a href="https://publications.waset.org/abstracts/search?q=skin%20cancer" title=" skin cancer"> skin cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=survival%20analyses" title=" survival analyses"> survival analyses</a> </p> <a href="https://publications.waset.org/abstracts/101504/prognosis-clinical-outcomes-and-short-term-survival-analyses-of-patients-with-cutaneous-melanomas" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/101504.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">170</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">3702</span> Ultra Wideband Breast Cancer Detection by Using SAR for Indication the Tumor Location</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Wittawat%20Wasusathien">Wittawat Wasusathien</a>, <a href="https://publications.waset.org/abstracts/search?q=Samran%20Santalunai"> Samran Santalunai</a>, <a href="https://publications.waset.org/abstracts/search?q=Thanaset%20Thosdeekoraphat"> Thanaset Thosdeekoraphat</a>, <a href="https://publications.waset.org/abstracts/search?q=Chanchai%20Thongsopa"> Chanchai Thongsopa</a> </p> <p class="card-text"><strong>Abstract:</strong></p> This paper presents breast cancer detection by observing the specific absorption rate (SAR) intensity for identification tumor location, the tumor is identified in coordinates (x,y,z) system. We examined the frequency between 4-8 GHz to look for the most appropriate frequency. Results are simulated in frequency 4-8 GHz, the model overview include normal breast with 50 mm radian, 5 mm diameter of tumor, and ultra wideband (UWB) bowtie antenna. The models are created and simulated in CST Microwave Studio. For this simulation, we changed antenna to 5 location around the breast, the tumor can be detected when an antenna is close to the tumor location, which the coordinate of maximum SAR is approximated the tumor location. For reliable, we experiment by random tumor location to 3 position in the same size of tumor and simulation the result again by varying the antenna position in 5 position again, and it also detectable the tumor position from the antenna that nearby tumor position by maximum value of SAR, which it can be detected the tumor with precision in all frequency between 4-8 GHz. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=specific%20absorption%20rate%20%28SAR%29" title="specific absorption rate (SAR)">specific absorption rate (SAR)</a>, <a href="https://publications.waset.org/abstracts/search?q=ultra%20wideband%20%28UWB%29" title=" ultra wideband (UWB)"> ultra wideband (UWB)</a>, <a href="https://publications.waset.org/abstracts/search?q=coordinates" title=" coordinates"> coordinates</a>, <a href="https://publications.waset.org/abstracts/search?q=cancer%20detection" title=" cancer detection"> cancer detection</a> </p> <a href="https://publications.waset.org/abstracts/10465/ultra-wideband-breast-cancer-detection-by-using-sar-for-indication-the-tumor-location" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/10465.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">403</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">3701</span> Effect of Different Porous Media Models on Drug Delivery to Solid Tumors: Mathematical Approach</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Mostafa%20Sefidgar">Mostafa Sefidgar</a>, <a href="https://publications.waset.org/abstracts/search?q=Sohrab%20Zendehboudi"> Sohrab Zendehboudi</a>, <a href="https://publications.waset.org/abstracts/search?q=Hossein%20Bazmara"> Hossein Bazmara</a>, <a href="https://publications.waset.org/abstracts/search?q=Madjid%20Soltani"> Madjid Soltani</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Based on findings from clinical applications, most drug treatments fail to eliminate malignant tumors completely even though drug delivery through systemic administration may inhibit their growth. Therefore, better understanding of tumor formation is crucial in developing more effective therapeutics. For this purpose, nowadays, solid tumor modeling and simulation results are used to predict how therapeutic drugs are transported to tumor cells by blood flow through capillaries and tissues. A solid tumor is investigated as a porous media for fluid flow simulation. Most of the studies use Darcy model for porous media. In Darcy model, the fluid friction is neglected and a few simplified assumptions are implemented. In this study, the effect of these assumptions is studied by considering Brinkman model. A multi scale mathematical method which calculates fluid flow to a solid tumor is used in this study to investigate how neglecting fluid friction affects the solid tumor simulation. In this work, the mathematical model in our previous studies is developed by considering two model of momentum equation for porous media: Darcy and Brinkman. The mathematical method involves processes such as fluid flow through solid tumor as porous media, extravasation of blood flow from vessels, blood flow through vessels and solute diffusion, convective transport in extracellular matrix. The sprouting angiogenesis model is used for generating capillary network and then fluid flow governing equations are implemented to calculate blood flow through the tumor-induced capillary network. Finally, the two models of porous media are used for modeling fluid flow in normal and tumor tissues in three different shapes of tumors. Simulations of interstitial fluid transport in a solid tumor demonstrate that the simplifications used in Darcy model affect the interstitial velocity and Brinkman model predicts a lower value for interstitial velocity than the values that Darcy model does. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=solid%20tumor" title="solid tumor">solid tumor</a>, <a href="https://publications.waset.org/abstracts/search?q=porous%20media" title=" porous media"> porous media</a>, <a href="https://publications.waset.org/abstracts/search?q=Darcy%20model" title=" Darcy model"> Darcy model</a>, <a href="https://publications.waset.org/abstracts/search?q=Brinkman%20model" title=" Brinkman model"> Brinkman model</a>, <a href="https://publications.waset.org/abstracts/search?q=drug%20delivery" title=" drug delivery"> drug delivery</a> </p> <a href="https://publications.waset.org/abstracts/37398/effect-of-different-porous-media-models-on-drug-delivery-to-solid-tumors-mathematical-approach" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/37398.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">306</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">3700</span> Development of a Computer Aided Diagnosis Tool for Brain Tumor Extraction and Classification</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Fathi%20Kallel">Fathi Kallel</a>, <a href="https://publications.waset.org/abstracts/search?q=Abdulelah%20Alabd%20Uljabbar"> Abdulelah Alabd Uljabbar</a>, <a href="https://publications.waset.org/abstracts/search?q=Abdulrahman%20Aldukhail"> Abdulrahman Aldukhail</a>, <a href="https://publications.waset.org/abstracts/search?q=Abdulaziz%20Alomran"> Abdulaziz Alomran</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The brain is an important organ in our body since it is responsible about the majority actions such as vision, memory, etc. However, different diseases such as Alzheimer and tumors could affect the brain and conduct to a partial or full disorder. Regular diagnosis are necessary as a preventive measure and could help doctors to early detect a possible trouble and therefore taking the appropriate treatment, especially in the case of brain tumors. Different imaging modalities are proposed for diagnosis of brain tumor. The powerful and most used modality is the Magnetic Resonance Imaging (MRI). MRI images are analyzed by doctor in order to locate eventual tumor in the brain and describe the appropriate and needed treatment. Diverse image processing methods are also proposed for helping doctors in identifying and analyzing the tumor. In fact, a large Computer Aided Diagnostic (CAD) tools including developed image processing algorithms are proposed and exploited by doctors as a second opinion to analyze and identify the brain tumors. In this paper, we proposed a new advanced CAD for brain tumor identification, classification and feature extraction. Our proposed CAD includes three main parts. Firstly, we load the brain MRI. Secondly, a robust technique for brain tumor extraction is proposed. This technique is based on both Discrete Wavelet Transform (DWT) and Principal Component Analysis (PCA). DWT is characterized by its multiresolution analytic property, that’s why it was applied on MRI images with different decomposition levels for feature extraction. Nevertheless, this technique suffers from a main drawback since it necessitates a huge storage and is computationally expensive. To decrease the dimensions of the feature vector and the computing time, PCA technique is considered. In the last stage, according to different extracted features, the brain tumor is classified into either benign or malignant tumor using Support Vector Machine (SVM) algorithm. A CAD tool for brain tumor detection and classification, including all above-mentioned stages, is designed and developed using MATLAB guide user interface. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=MRI" title="MRI">MRI</a>, <a href="https://publications.waset.org/abstracts/search?q=brain%20tumor" title=" brain tumor"> brain tumor</a>, <a href="https://publications.waset.org/abstracts/search?q=CAD" title=" CAD"> CAD</a>, <a href="https://publications.waset.org/abstracts/search?q=feature%20extraction" title=" feature extraction"> feature extraction</a>, <a href="https://publications.waset.org/abstracts/search?q=DWT" title=" DWT"> DWT</a>, <a href="https://publications.waset.org/abstracts/search?q=PCA" title=" PCA"> PCA</a>, <a href="https://publications.waset.org/abstracts/search?q=classification" title=" classification"> classification</a>, <a href="https://publications.waset.org/abstracts/search?q=SVM" title=" SVM"> SVM</a> </p> <a href="https://publications.waset.org/abstracts/81523/development-of-a-computer-aided-diagnosis-tool-for-brain-tumor-extraction-and-classification" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/81523.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">250</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">3699</span> Correlation of Clinical and Sonographic Findings with Cytohistology for Diagnosis of Ovarian Tumours</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Meenakshi%20Barsaul%20Chauhan">Meenakshi Barsaul Chauhan</a>, <a href="https://publications.waset.org/abstracts/search?q=Aastha%20Chauhan"> Aastha Chauhan</a>, <a href="https://publications.waset.org/abstracts/search?q=Shilpa%20Hurmade"> Shilpa Hurmade</a>, <a href="https://publications.waset.org/abstracts/search?q=Rajeev%20Sen"> Rajeev Sen</a>, <a href="https://publications.waset.org/abstracts/search?q=Jyotsna%20Sen"> Jyotsna Sen</a>, <a href="https://publications.waset.org/abstracts/search?q=Monika%20Dalal"> Monika Dalal</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction: Ovarian masses are common forms of neoplasm in women and represent 2/3rd of gynaecological malignancies. A pre-operative suggestion of malignancy can guide the gynecologist to refer women with suspected pelvic mass to a gynecological oncologist for appropriate therapy and optimized treatment, which can improve survival. In the younger age group preoperative differentiation into benign or malignant pathology can decide for conservative or radical surgery. Imaging modalities have a definite role in establishing the diagnosis. By using International Ovarian Tumor Analysis (IOTA) classification with sonography, costly radiological methods like Magnetic Resonance Imaging (MRI) / computed tomography (CT) scan can be reduced, especially in developing countries like India. Thus, this study is being undertaken to evaluate the role of clinical methods and sonography for diagnosis of the nature of the ovarian tumor. Material And Methods: This prospective observational study was conducted on 40 patients presenting with ovarian masses, in the Department of Obstetrics and Gynaecology, at a tertiary care center in northern India. Functional cysts were excluded. Ultrasonography and color Doppler were performed on all the cases.IOTA rules were applied, which take into account locularity, size, presence of solid components, acoustic shadow, dopper flow etc . Magnetic Resonance Imaging (MRI) / computed tomography (CT) scans abdomen and pelvis were done in cases where sonography was inconclusive. In inoperable cases, Fine needle aspiration cytology (FNAC) was done. The histopathology report after surgery and cytology report after FNAC was correlated statistically with the pre-operative diagnosis made clinically and sonographically using IOTA rules. Statistical Analysis: Descriptive measures were analyzed by using mean and standard deviation and the Student t-test was applied and the proportion was analyzed by applying the chi-square test. Inferential measures were analyzed by sensitivity, specificity, negative predictive value, and positive predictive value. Results: Provisional diagnosis of the benign tumor was made in 16(42.5%) and of the malignant tumor was made in 24(57.5%) patients on the basis of clinical findings. With IOTA simple rules on sonography, 15(37.5%) were found to be benign, while 23 (57.5%) were found to be malignant and findings were inconclusive in 2 patients (5%). FNAC/Histopathology reported that benign ovarian tumors were 14 (35%) and 26(65%) were malignant, which was taken as the gold standard. The clinical finding alone was found to have a sensitivity of 66.6% and a specificity of 90.9%. USG alone had a sensitivity of 86% and a specificity of 80%. When clinical findings and IOTA simple rules of sonography were combined (excluding inconclusive masses), the sensitivity and specificity were 83.3% and 92.3%, respectively. While including inconclusive masses, sensitivity came out to be 91.6% and specificity was 89.2. Conclusion: IOTA's simple sonography rules are highly sensitive and specific in the prediction of ovarian malignancy and also easy to use and easily reproducible. Thus, combining clinical examination with USG will help in the better management of patients in terms of time, cost and better prognosis. This will also avoid the need for costlier modalities like CT, and MRI. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=benign" title="benign">benign</a>, <a href="https://publications.waset.org/abstracts/search?q=international%20ovarian%20tumor%20analysis%20classification" title=" international ovarian tumor analysis classification"> international ovarian tumor analysis classification</a>, <a href="https://publications.waset.org/abstracts/search?q=malignant" title=" malignant"> malignant</a>, <a href="https://publications.waset.org/abstracts/search?q=ovarian%20tumours" title=" ovarian tumours"> ovarian tumours</a>, <a href="https://publications.waset.org/abstracts/search?q=sonography" title=" sonography"> sonography</a> </p> <a href="https://publications.waset.org/abstracts/160067/correlation-of-clinical-and-sonographic-findings-with-cytohistology-for-diagnosis-of-ovarian-tumours" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/160067.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">80</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">3698</span> Sequential Release of Dual Drugs Using Thermo-Sensitive Hydrogel for Tumor Vascular Inhibition and to Enhance the Efficacy of Chemotherapy</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Haile%20F.%20Darge">Haile F. Darge</a>, <a href="https://publications.waset.org/abstracts/search?q=Hsieh%20C.%20Tsai"> Hsieh C. Tsai</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The tumor microenvironment affects the therapeutic outcomes of cancer disease. In a malignant tumor, overexpression of vascular endothelial growth factor (VEGF) provokes the production of pathologic vascular networks. This results in a hostile tumor environment that hinders anti-cancer drug activities and profoundly fuels tumor progression. In this study, we develop a strategy of sequential sustain release of the anti-angiogenic drug: Bevacizumab(BVZ), and anti-cancer drug: Doxorubicin(DOX) which had a synergistic effect on cancer treatment. Poly (D, L-Lactide)- Poly (ethylene glycol) –Poly (D, L-Lactide) (PDLLA-PEG-PDLLA) thermo-sensitive hydrogel was used as a vehicle for local delivery of drugs in a single platform. The in vitro release profiles of the drugs were investigated and confirmed a relatively rapid release of BVZ (73.56 ± 1.39%) followed by Dox (61.21 ± 0.62%) for a prolonged period. The cytotoxicity test revealed that the copolymer exhibited negligible cytotoxicity up to 2.5 mg ml-1 concentration on HaCaT and HeLa cells. The in vivo study on Hela xenograft nude mice verified that hydrogel co-loaded with BVZ and DOX displayed the highest tumor suppression efficacy for up to 36 days with pronounce anti-angiogenic effect of BVZ and with no noticeable damage on vital organs. Therefore, localized co-delivery of anti-angiogenic drug and anti-cancer drugs by the hydrogel system may be a promising approach for enhanced chemotherapeutic efficacy in cancer treatment. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=anti-angiogenesis" title="anti-angiogenesis">anti-angiogenesis</a>, <a href="https://publications.waset.org/abstracts/search?q=chemotherapy" title=" chemotherapy"> chemotherapy</a>, <a href="https://publications.waset.org/abstracts/search?q=controlled%20release" title=" controlled release"> controlled release</a>, <a href="https://publications.waset.org/abstracts/search?q=thermo-sensitive%20hydrogel" title=" thermo-sensitive hydrogel"> thermo-sensitive hydrogel</a> </p> <a href="https://publications.waset.org/abstracts/118621/sequential-release-of-dual-drugs-using-thermo-sensitive-hydrogel-for-tumor-vascular-inhibition-and-to-enhance-the-efficacy-of-chemotherapy" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/118621.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">134</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">3697</span> Low SPOP Expression and High MDM2 expression Are Associated with Tumor Progression and Predict Poor Prognosis in Hepatocellular Carcinoma</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Chang%20Liang">Chang Liang</a>, <a href="https://publications.waset.org/abstracts/search?q=Weizhi%20Gong"> Weizhi Gong</a>, <a href="https://publications.waset.org/abstracts/search?q=Yan%20Zhang"> Yan Zhang</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Purpose: Hepatocellular carcinoma (HCC) is a malignant tumor with a high mortality rate and poor prognosis worldwide. Murine double minute 2 (MDM2) regulates the tumor suppressor p53, increasing cancer risk and accelerating tumor progression. Speckle-type POX virus and zinc finger protein (SPOP), a key of subunit of Cullin-Ring E3 ligase, inhibits tumor genesis and progression by the ubiquitination of its downstream substrates. This study aimed to clarify whether SPOP and MDM2 are mutually regulated in HCC and the correlation between SPOP and MDM2 and the prognosis of HCC patients. Methods: First, the expression of SPOP and MDM2 in HCC tissues were detected by TCGA database. Then, 53 paired samples of HCC tumor and adjacent tissues were collected to evaluate the expression of SPOP and MDM2 using immunohistochemistry. Chi-square test or Fisher’s exact test were used to analyze the relationship between clinicopathological features and the expression levels of SPOP and MDM2. In addition, Kaplan‒Meier curve analysis and log-rank test were used to investigate the effects of SPOP and MDM2 on the survival of HCC patients. Last, the Multivariate Cox proportional risk regression model analyzed whether the different expression levels of SPOP and MDM2 were independent risk factors for the prognosis of HCC patients. Results: Bioinformatics analysis revealed the low expression of SPOP and high expression of MDM2 were related to worse prognosis of HCC patients. The relationship between the expression of SPOP and MDM2 and tumor stem-like features showed an opposite trend. The immunohistochemistry showed the expression of SPOP protein was significantly downregulated while MDM2 protein significantly upregulated in HCC tissue compared to that in para-cancerous tissue. Tumors with low SPOP expression were related to worse T stage and Barcelona Clinic Liver Cancer (BCLC) stage, but tumors with high MDM2 expression were related to worse T stage, M stage, and BCLC stage. Kaplan–Meier curves showed HCC patients with high SPOP expression and low MDM2 expression had better survival than those with low SPOP expression and high MDM2 expression (P < 0.05). A multivariate Cox proportional risk regression model confirmed that a high MDM2 expression level was an independent risk factor for poor prognosis in HCC patients (P <0.05). Conclusion: The expression of SPOP protein was significantly downregulated, while the expression of MDM2 significantly upregulated in HCC. The low expression of SPOP and high expression. of MDM2 were associated with malignant progression and poor prognosis of HCC patients, indicating a potential therapeutic target for HCC patients. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=hepatocellular%20carcinoma" title="hepatocellular carcinoma">hepatocellular carcinoma</a>, <a href="https://publications.waset.org/abstracts/search?q=murine%20double%20minute%202" title=" murine double minute 2"> murine double minute 2</a>, <a href="https://publications.waset.org/abstracts/search?q=speckle-type%20POX%20virus%20and%20zinc%20finger%20protein" title=" speckle-type POX virus and zinc finger protein"> speckle-type POX virus and zinc finger protein</a>, <a href="https://publications.waset.org/abstracts/search?q=ubiquitination" title=" ubiquitination"> ubiquitination</a> </p> <a href="https://publications.waset.org/abstracts/148798/low-spop-expression-and-high-mdm2-expression-are-associated-with-tumor-progression-and-predict-poor-prognosis-in-hepatocellular-carcinoma" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/148798.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">144</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">3696</span> ESDN Expression in the Tumor Microenvironment Coordinates Melanoma Progression</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Roberto%20Coppo">Roberto Coppo</a>, <a href="https://publications.waset.org/abstracts/search?q=Francesca%20Orso"> Francesca Orso</a>, <a href="https://publications.waset.org/abstracts/search?q=Daniela%20Dettori"> Daniela Dettori</a>, <a href="https://publications.waset.org/abstracts/search?q=Elena%20Quaglino"> Elena Quaglino</a>, <a href="https://publications.waset.org/abstracts/search?q=Lei%20Nie"> Lei Nie</a>, <a href="https://publications.waset.org/abstracts/search?q=Mehran%20M.%20Sadeghi"> Mehran M. Sadeghi</a>, <a href="https://publications.waset.org/abstracts/search?q=Daniela%20Taverna"> Daniela Taverna</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Malignant melanoma is currently the fifth most common cancer in the white population and it is fatal in its metastatic stage. Several research studies in recent years have provided evidence that cancer initiation and progression are driven by genetic alterations of the tumor and paracrine interactions between tumor and microenvironment. Scattered data show that the Endothelial and Smooth muscle cell-Derived Neuropilin-like molecule (ESDN) controls cell proliferation and movement of stroma and tumor cells. To investigate the role of ESDN in the tumor microenvironment during melanoma progression, murine melanoma cells (B16 or B16-F10) were injected in ESDN knockout mice in order to evaluate how the absence of ESDN in stromal cells could influence melanoma progression. While no effect was found on primary tumor growth, increased cell extravasation and lung metastasis formation was observed in ESDN knockout mice compared to wild type controls. In order to understand how cancer cells cross the endothelial barrier during metastatic dissemination in an ESDN-null microenvironment, structure, and permeability of lung blood vessels were analyzed. Interestingly, ESDN knockout mice showed structurally altered and more permeable vessels compared to wild type animals. Since cell surface molecules mediate the process of tumor cell extravasation, the expression of a panel of extravasation-related ligands and receptors was analyzed. Importantly, modulations of N-cadherin, E-selectin, ICAM-1 and VAP-1 were observed in ESDN knockout endothelial cells, suggesting the presence of a favorable tumor microenvironment which facilitates melanoma cell extravasation and metastasis formation in the absence of ESDN. Furthermore, a potential contribution of immune cells in tumor dissemination was investigated. An increased recruitment of macrophages in the lungs of ESDN knockout mice carrying subcutaneous B16-F10 tumors was found. In conclusion, our data suggest a functional role of ESDN in the tumor microenvironment during melanoma progression and the identification of the mechanisms that regulate tumor cell extravasation could lead to the development of new therapies to reduce metastasis formation. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=melanoma" title="melanoma">melanoma</a>, <a href="https://publications.waset.org/abstracts/search?q=tumor%20microenvironment" title=" tumor microenvironment"> tumor microenvironment</a>, <a href="https://publications.waset.org/abstracts/search?q=extravasation" title=" extravasation"> extravasation</a>, <a href="https://publications.waset.org/abstracts/search?q=cell%20surface%20molecules" title=" cell surface molecules"> cell surface molecules</a> </p> <a href="https://publications.waset.org/abstracts/44830/esdn-expression-in-the-tumor-microenvironment-coordinates-melanoma-progression" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/44830.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">334</span> </span> </div> </div> <ul class="pagination"> <li class="page-item disabled"><span class="page-link">&lsaquo;</span></li> <li class="page-item active"><span class="page-link">1</span></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=malignant%20mixed%20mullerian%20tumor&page=2">2</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=malignant%20mixed%20mullerian%20tumor&page=3">3</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=malignant%20mixed%20mullerian%20tumor&page=4">4</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=malignant%20mixed%20mullerian%20tumor&page=5">5</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=malignant%20mixed%20mullerian%20tumor&page=6">6</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=malignant%20mixed%20mullerian%20tumor&page=7">7</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=malignant%20mixed%20mullerian%20tumor&page=8">8</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=malignant%20mixed%20mullerian%20tumor&page=9">9</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=malignant%20mixed%20mullerian%20tumor&page=10">10</a></li> <li class="page-item disabled"><span class="page-link">...</span></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=malignant%20mixed%20mullerian%20tumor&page=124">124</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=malignant%20mixed%20mullerian%20tumor&page=125">125</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=malignant%20mixed%20mullerian%20tumor&page=2" rel="next">&rsaquo;</a></li> </ul> </div> </main> <footer> <div id="infolinks" class="pt-3 pb-2"> <div class="container"> <div style="background-color:#f5f5f5;" class="p-3"> <div class="row"> <div class="col-md-2"> <ul class="list-unstyled"> About <li><a href="https://waset.org/page/support">About Us</a></li> <li><a href="https://waset.org/page/support#legal-information">Legal</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/WASET-16th-foundational-anniversary.pdf">WASET celebrates its 16th foundational anniversary</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Account <li><a href="https://waset.org/profile">My Account</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Explore <li><a href="https://waset.org/disciplines">Disciplines</a></li> <li><a href="https://waset.org/conferences">Conferences</a></li> <li><a href="https://waset.org/conference-programs">Conference Program</a></li> <li><a href="https://waset.org/committees">Committees</a></li> <li><a href="https://publications.waset.org">Publications</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Research <li><a href="https://publications.waset.org/abstracts">Abstracts</a></li> <li><a href="https://publications.waset.org">Periodicals</a></li> <li><a href="https://publications.waset.org/archive">Archive</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Open Science <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Science-Philosophy.pdf">Open Science Philosophy</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Science-Award.pdf">Open Science Award</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Society-Open-Science-and-Open-Innovation.pdf">Open Innovation</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Postdoctoral-Fellowship-Award.pdf">Postdoctoral Fellowship Award</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Scholarly-Research-Review.pdf">Scholarly Research Review</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Support <li><a href="https://waset.org/page/support">Support</a></li> <li><a href="https://waset.org/profile/messages/create">Contact Us</a></li> <li><a href="https://waset.org/profile/messages/create">Report Abuse</a></li> </ul> </div> </div> </div> </div> </div> <div class="container text-center"> <hr style="margin-top:0;margin-bottom:.3rem;"> <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank" class="text-muted small">Creative Commons Attribution 4.0 International License</a> <div id="copy" class="mt-2">© 2024 World Academy of Science, Engineering and Technology</div> </div> </footer> <a href="javascript:" id="return-to-top"><i class="fas fa-arrow-up"></i></a> <div class="modal" id="modal-template"> <div class="modal-dialog"> <div class="modal-content"> <div class="row m-0 mt-1"> <div class="col-md-12"> <button type="button" class="close" data-dismiss="modal" aria-label="Close"><span aria-hidden="true">×</span></button> </div> </div> <div class="modal-body"></div> </div> </div> </div> <script src="https://cdn.waset.org/static/plugins/jquery-3.3.1.min.js"></script> <script src="https://cdn.waset.org/static/plugins/bootstrap-4.2.1/js/bootstrap.bundle.min.js"></script> <script src="https://cdn.waset.org/static/js/site.js?v=150220211556"></script> <script> jQuery(document).ready(function() { /*jQuery.get("https://publications.waset.org/xhr/user-menu", function (response) { jQuery('#mainNavMenu').append(response); });*/ jQuery.get({ url: "https://publications.waset.org/xhr/user-menu", cache: false }).then(function(response){ jQuery('#mainNavMenu').append(response); }); }); </script> </body> </html>